… patients with multiple myeloma experience relapse and re-treating with the … we are accelerating its development in earlier lines of … 7 phase III trial.1 The trial demonstrated that … by-us-fda-for-use-in-treatment-of-relapsedrefractory-multiple-myeloma/

… with relapsed or refractory multiple myeloma who have received at … phase III DREAMM-7 trial, which showed Blenrep BVd … —over 70% of the treatment population. Blenrep combinations are … including China, where the drug has received Breakthrough Therapy …

… promising new pathway for developing therapies to fight cancer … in several clinical trials to treat multiple myeloma, kidney cancer, medulloblastoma, … use for a drug candidate. Pharmaceutical companies in their … to suppose that AI development would one day not …

… blockbuster blood cancer drug developed by GSK, in … drugs for adult patients with relapsed or refractory multiple myeloma … with multiple myeloma experience relapse and re-treating with … trial results as a sole treatment for a later stage of multiple myeloma …

… pharmaceutical giant pulled the multiple myeloma therapy from the market, the FDA approved the drug … it left. Multiple myeloma is a blood cancer that develops in plasma cells … and BMS drugs as a second-line or later treatment. The FDA said …

… the DREAMM-7 phase 3 trial, which showed that in patients … type of treatment works to treat multiple myeloma. Transcript: How do antibody-drug conjugates such … -by-us-fda-for-use-in-treatment-of-relapsedrefractory-multiple-myeloma/ "FDA Approves …

… that the US Food and Drug Administration (FDA) has approved its cancer … pivotal phase III DREAMM-7 trial, which showed that Blenrep combined … option in the evolving treatment landscape for multiple myeloma, expanding access to an …

… for the treatment of certain adults with relapsed or refractory multiple myeloma. “With … the phase 3 DREAMM-7 trial, in which patients in the … agent. In July, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted …

GSK announces that the US FDA has approved Blenrep (belantamab … the treatment of adult patients with relapsed or refractory multiple myeloma after … results of a Phase III trial that showed a 51% … Blenrep in earlier lines of treatment, with new data expected …

… treatment response improvements over a similar regimen based on bortezomib. The FDA … Blenrep, the FDA’s Oncologic Drugs Advisory Committee found … or refractory multiple myeloma, under the FDA’s accelerated pathway … III DREAMM-3 trial, the pharma decided to pull …